Forge Investment Outlook Q2 2024Road to Recovery: Private Market Accelerates in Q1
Forge Investment Outlook Q2 2024
Trading
Data
Solutions
Insights
About
ADARx Pharmaceuticals is a company that specializes in genetic medicine designed to treat human diseases and ailments using mRNA transcripts. ADARx researches and develops its therapies through oligonucleotides delivery technology. The firm focuses on three main disease treatments: genetic diseases, cardiometabolic diseases, and central nervous system (CNS) diseases.
ADARx Pharmaceuticals is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
If you own ADARx Pharmaceuticals pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.
Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.
ADARx Pharmaceuticals is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
| Date | Funding Round | Funding Raised | Price per Share | Last Known Valuation |
|---|---|---|---|---|
| 8/9/2023 | Series C | $200MM raised | $XXX.XX | $XXX.XX |
| 1/20/2023 | Series B-1 | $46MM raised | $XXX.XX | $XXX.XX |
| 9/8/2021 | Series B | $75MM raised | $XXX.XX | $XXX.XX |
| 5/14/2021 | Series A | $31.5MM raised | $XXX.XX | $XXX.XX |
